Pioneering Pain Management: High-Frequency Electrical Stimulation Devices

By HEOR Staff Writer

October 27, 2023

High-frequency electrical stimulation devices

The Current Opioid Crisis and the Treatment of Post-Caesarean Pain

Systemic opioids are the medication that is utilised the most frequently, despite the fact that pain management following a caesarean delivery is a complicated issue. Having said that, this method is not without its flaws. The overprescription of opioids is a key cause, and it is estimated that 1.2 million of the caesarean births performed annually in the United States result in the disposal of 12 million unneeded tablets. There is a high likelihood that these unused tablets will be abused, which will contribute to the continuing opioid problem.

 

A Novel Technique for the Management of Pain

A recent study found that devices that use high-frequency electrical stimulation could be an effective solution to the problem. According to the findings of the study, women who had caesarean deliveries followed by transcutaneous treatment using a high-frequency electrical stimulation device required around 47 percent less opioid analgesic medication while they were in the hospital. In addition, these individuals reported levels of discomfort that were comparable to those reported by patients who had used a sham device.

High-frequency electrical stimulation devices

This breakthrough has the potential to constitute a key step towards lowering the use of opioids, avoiding overprescribing, and preventing dependence from developing. Because it is estimated that 36,000 to 72,000 people in the United States develop a dependence on opioids each year after having a caesarean delivery, finding effective measures to reduce opioid use continues to be a public health priority.

Reference url

Recent Posts

clinical trial monitoring
Clinical Trial Monitoring: Insights from Q1 2026 EU/EEA Report

By HEOR Staff Writer

May 22, 2026

Clinical trial monitoring shows that in the first quarter of 2026, an average of 208 new clinical trial applications were submitted monthly through the Clinical Trials Information System, yielding 668 total submissions of which 538 received authorisation. The median time from submission to decisi...
Novartis oncology advancements
Novartis Oncology Advancements: Key Trial Findings and Market Implications
Novartis oncology advancements take center stage as the company prepares to unveil findings from more than 65 abstracts at the upcoming ASCO and EHA meetings. These presentations spotlight progress with Pluvicto, Kisqali, and Scemblix while reinforcing the firm’s commitment to transforming outcom...
EUDAMED Implementation 2026
EUDAMED Implementation 2026: Key Changes and National Adaptations
The EUDAMED Implementation 2026 will require mandatory use of four key modules in the European database on medical devices from 28 May 2026. These cover registration of economic operators, device registration via UDI, notified bodies and certificates, plus market surveillance, following earlier v...